Download Image
    
Share
  
Post
Zansecimab for COVID-19
1 study with 95 patients
Hospital Icon Control
Hospital Icon Zansecimab Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Zansecimab studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -36% Mortality -36% RCTs -36% Late -36% Favorszansecimab Favorscontrol
Zansecimab (LY3127804) is an intravenous monoclonal antibody that targets Angiopoietin-2 (Ang-2), a key protein in vascular inflammation.
Jan 31
2022
 Jones et al., Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, doi:10.1177/11795484221119316 Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19
36% higher mortality (p=0.58) and 70% higher combined mortality/intubation (p=0.28). RCT 95 hospitalized patients with COVID-19 pneumonia showing no significant differences with zansecimab (LY3127804, anti-Angiopoietin-2 antibody).